The accuracy of tumor-intrinsic biomarkers such as PD-L1 and TMB has decreased with the addition of chemotherapeutic regimens in NSCLC neoadjuvant immunotherapy that are mutagenic and may thus induce a higher TMB score. The gene discussed is CD274; the disease is neoplasm.